Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13939MR)

This product GTTS-WQ13939MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13939MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1950MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ5562MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ1581MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ7873MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ13049MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5603MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ9186MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ6262MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR-6261
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW